SEC Form 4 · accession 0001209191-17-052475
ImmunityBio, Inc. · IBRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Steve Gorlin
Director
Period of report
Sep 8, 2017
Accepted (ET)
Sep 12, 2017 · 6:12 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001326110
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Sep 8, 2017 | S | 14,723 | $6.1208 | D | 375,002 | D | |
| Common StockF2 | Sep 11, 2017 | S | 53,307 | $6.0305 | D | 321,695 | D | |
| Common StockF3 | Sep 12, 2017 | S | 35,811 | $6.027 | D | 285,884 | D | |
| Common Stock | holding | — | — | — | 521,720 | I | By spouse |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents the weighted average share price of an aggregate total of 14,723 shares sold in the price range of $6.1031 to $6.15 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F2Represents the weighted average share price of an aggregate total of 53,307 shares sold in the price range of $6.00 to $6.08 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F3Represents the weighted average share price of an aggregate total of 35,811 shares sold in the price range of $6.00 to $6.10 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.